We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY. Sanofi (SNY)’s share was trading at $51.06 ...

The Business Research Company's Myozyme Global market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...

Date 2025-02-06 12:45:42 (MENAFN - EIN Presswire) The Business Research Company Myozyme Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 ...

Among the rare disease drugs in the Pompe franchise, Myozyme sales declined 17% year over year to €132 million due to patients switching to Nexviazyme. Fabrazyme sales were €269 million, up 12 ...

Amicus Therapeutics' shares are down 15% recently despite a profitable Q3 2024 and raised FY2024 outlook. Click here to find out why I rate FOLD stock a Buy.

Royalty Pharma now anticipates 2023 Adjusted Cash Receipts (1) (non-GAAP) to be between $2,900 million and $2,975 million (previously $2,850 million to $2,950 million), excluding future ...

The product, which is marketed in Europe under the name Myozyme, accounted for more than €1 billion (about $1.1 billion) in revenue last year. Sanofi’s second Pompe therapy is an enzyme ...

Sanofi has announced that its long-term enzyme replacement therapy will now be available on the NHS to patients with Pompe disease, following a recommendation from the National Institute for Health ...

The first round of the 2022 National Reimbursement Drug List (NRDL) review took longer than expected, partly as a result of the large number of entries submitted. In the first half of July, the ...

That’s 30 meters farther than the change reported in patients treated with Myozyme. European approval of Nexviadyme covers both late-onset and infantile-onset Pompe disease.